Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats

Behavioural Pharmacology

Volumn 20, Issue 8, 2009, Pages 688-694

  Brennan, Katharine A ^a,b   Carati, Caleb ^b   Lea, Rod A ^a   Fitzmaurice, Paul S ^a   Schenk, Susan ^b  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

3,4 methylenedioxymethamphetamine; D1 like receptor; D2 like receptor; Dopamine; Eticlopride; Methamphetamine; Rat; SCH23390; Self administration

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARPROFEN; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ETICLOPRIDE; HEPARIN; METHAMPHETAMINE; PENICILLIN G POTASSIUM; PENTOBARBITAL; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SELF ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; OUTCOME ASSESSMENT; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; CENTRAL NERVOUS SYSTEM; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SELF ADMINISTRATION;

EID: 73949104627     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328333a28d     Document Type: Article

References (35)

1. Bari AA, Pierce RC (2005). D1-like and D2 dopamine receptor antagonists administered into the shell subregion of the rat nucleus accumbens decrease cocaine, but not food, reinforcement. Neuroscience 135:959-968.
2. Barrett AC, Miller JR, Dohrmann JM, Caine SB (2004). Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 47 (Suppl 1):256-273.
3. Baumann MH, Ayestas MA, Sharpe LG, Lewis DB, Rice KC, Rothman RB (2002). Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. J Pharmacol Exp Ther 301:1190-1197.
4. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (2005). N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30:550-560.
5. Baumann MH, Clark RD, Franken FH, Rutter JJ, Rothman RB (2008). Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 152:773-784.
6. Botly LC, Burton CL, Rizos Z, Fletcher PJ (2008). Characterization of methylphenidate self-administration and reinstatement in the rat. Psycho-pharmacology (Berl) 199:55-66.
7. Brennan KA, Lake B, Hely LS, Jones K, Gittings D, Colussi-Mas J, et al. (2007). N-benzylpiperazine has characteristics of a drug of abuse. Behav Pharmacol 18:785-790.
8. Caine SB, Koob GF (1994). Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J Pharmacol Exp Ther 270:209-218.
9. Caine SB, Heinrichs SC, Coffin VL, Koob GF (1995). Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res 692:47-56.
10. Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, et al. (2002). Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci 22:2977-2988.
11. Daniela E, Brennan K, Gittings D, Hely L, Schenk S (2004). Effect of SCH 23390 on (± )-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav 77:745-750.
12. De Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, et al. (2008). Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131:2936-2945.
13. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphe-tamine (MDMA, ecstasy). Pharmacol Rev 55:463-508.
14. Gudelsky GA, Yamamoto BK (2008). Actions of 3,4-methylenedioxymethamphe- tamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 90:198-207.
15. Haile CN, Kosten TA (2001). Differential effects of D1-and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats. J Pharmacol Exp Ther 299:509-518.
16. Kindlundh-Hogberg AM, Svenningsson P, Schioth HB (2006). Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain. Neuropharmacology 51:838-847.
17. Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L (2006). Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl) 186:48-53.
18. Lile JA, Morgan D, Birmingham AM, Davies HM, Nader MA (2004). Effects of the dopamine reuptake inhibitor PTT on reinstatement and on food-and cocaine-maintained responding in rhesus monkeys. Psychopharmacology (Berl) 174:246-253.
19. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, et al. (2008). Persistent cognitive and dopamine transporter deficits in abstinent metham-phetamine users. Synapse 62:91-100.
20. Melega WP, Jorgensen MJ, Lacan G, Way BM, Pham J, Morton G, et al. (2008). Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. Neuropsychopharmacology 33:1441-1452.
21. Panlilio LV, Goldberg SR (2007). Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 102:1863-1870.
22. Ranaldi R, Wang Z, Woolverton WL (2001). Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys. Drug Alcohol Depend 64:209-217.
23. Schenk S, Gittings D, Johnstone M, Daniela E (2003). Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 169:21-27.
24. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC (2007). MDMA self-administration in rats: acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci 26:3229-3236.
25. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2005). Prolonged exposure of rats to intravenous methamphetamine: behavioral and neuro-chemical characterization. Psychopharmacology (Berl) 180:501-512.
26. Self DW (2004). Regulation of drug-taking and-seeking behaviors by neuroadaptations in the mesolimbic dopamine system. Neuropharmacology 47 (Suppl 1):242-255.
27. Self DW, Stein L (1992). The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats. Brain Res 582:349-352.
28. Shepard JD, Chuang DT, Shaham Y, Morales M (2006). Effect of methamphe-tamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology (Berl) 185:505-513.
29. Stefanski R, Ladenheim B, Lee SH, Cadet JL, Goldberg SR (1999). Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine. Eur J Pharmacol 371:123-135.
30. Stefanski R, Ziolkowska B, Kusmider M, Mierzejewski P, Wyszogrodzka E, Kolomanska P, et al. (2007). Active versus passive cocaine administration: differences in the neuroadaptive changes in the brain dopaminergic system. Brain Res 1157:1-10.
31. Tong J, Ross BM, Schmunk GA, Kalasinsky KS, Furukawa Y, Ang LC, et al. (2003). Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am J Psychiatry 160:896-903.
32. UNODC (2008). United Nations Office of Drugs and Crime: World Drug Report. http://www.unodc.org/unodc/en/data-and-analysis/WDR-2008.html [Accessed 11/03/09].
33. Weed MR, Woolverton WL (1995). The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys. J Pharmacol Exp Ther 275:1367-1374.
34. Woolverton WL, Goldberg LI, Ginos JZ (1984). Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J Pharmacol Exp Ther 230:678-683.
35. Worsley JN, Moszczynska A, Falardeau P, Kalasinsky KS, Schmunk G, Guttman M, et al. (2000). Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry 5:664-672.